<?xml version="1.0" encoding="UTF-8"?>
<p>The nonenveloped dsRNA Reovirus Serotype 3-Dearing Strain known as Reolysin has been shown to replicate in specifically transformed cells possessing an activated RAS signaling pathway, which makes it a potential candidate for anticancer therapy [
 <xref rid="B136-biomedicines-08-00060" ref-type="bibr">136</xref>,
 <xref rid="B137-biomedicines-08-00060" ref-type="bibr">137</xref>,
 <xref rid="B138-biomedicines-08-00060" ref-type="bibr">138</xref>]. The inhibition of dsRNA-activated protein kinase (PKR) in Ras-activated cells inhibits autophosphorylation of PKR, permitting viral translation and oncolysis in tumor cells [
 <xref rid="B36-biomedicines-08-00060" ref-type="bibr">36</xref>,
 <xref rid="B114-biomedicines-08-00060" ref-type="bibr">114</xref>]. As Ras pathway activation occurs in approximately 60% of metastatic melanoma patients, it provides a great opportunity for Reolysin testing in malignancy treatment [
 <xref rid="B139-biomedicines-08-00060" ref-type="bibr">139</xref>,
 <xref rid="B140-biomedicines-08-00060" ref-type="bibr">140</xref>].
</p>
